logo

Auris Medical Holding Ag (EARS)



Trade EARS now with
  Date
  Headline
9/17/2020 8:16:12 AM Auris Medical Holding H1 Net Loss CHF 2.7 Mln Or CHF 0.58 Per Share
9/3/2020 8:33:31 AM Auris Medical Announces Positive Interim Data From TRAVERS Phase 2 Study With AM-125 In Vertigo
3/5/2020 8:44:41 AM Auris Medical Updates On Ongoing Clinical Trials With Intranasal Betahistine
2/25/2020 8:36:16 AM Auris Medical Highlights Publication Of Results Demonstrating Betahistine’s Antiepileptogenic & Anticonvulsant Activity
12/30/2019 8:31:39 AM Auris Medical Reports Formation Of New Subsidiary For Development Projects In Tinnitus And Hearing Loss
10/11/2019 8:32:34 AM Auris Medical Report Positive Interim Results From Phase 1b Trial With AM-201
7/3/2019 9:03:24 AM Auris Medical Completes Enrollment In Phase 1b Proof-of-concept Trial Of AM-201
2/1/2019 7:33:21 AM Auris Medical Announces Full Repayment Of Hercules Loan Facility
1/29/2019 7:35:19 AM Auris Medical Intends To Relocate Domicile From Zug, Switzerland To Hamilton, Bermuda
12/6/2018 7:33:19 AM Auris Medical Announces Strategic Expansion For Intranasal Betahistine Development Program
11/20/2018 9:23:12 AM Auris Medical Says FDA Supports Planned Conduct Of Multiple Dose Phase 1 Trial With AM-201
11/15/2018 6:48:15 AM Auris Medical Holding Q3 Net Loss CHF 3.0 Mln Or CHF 0.14 Per Share
10/17/2018 6:48:44 AM Auris Medical Reports Positive Results From Second Phase 1 Clinical Trial With Intranasal Betahistine
8/30/2018 8:16:37 AM Auris Medical Gets FDA Guidance At Type C Meeting For AM-111 In Treatment Of Sudden Sensorineural Hearing Loss